KQB548 (BAY 3771249)
KRAS G12D-mutated tumors (e.g., pancreatic, colorectal, lung cancer)
Phase 1Active
Key Facts
Indication
KRAS G12D-mutated tumors (e.g., pancreatic, colorectal, lung cancer)
Phase
Phase 1
Status
Active
Company
About Kumquat Biosciences
Kumquat Biosciences is a private, clinical-stage oncology biotech leveraging deep KRAS pathway expertise to develop small molecule inhibitors and combination therapies aimed at historically undruggable targets. The company has rapidly advanced its lead KRAS G12D inhibitor into Phase I clinical trials through a significant global collaboration with pharmaceutical giant Bayer. With a focus on targeted and immuno-oncology, Kumquat aims to address high-unmet-need cancers and overcome drug resistance.
View full company profile